Phase I - Development of Automated Hybrid Urine Cell Filtration Device Phase II - Validation of Clinically Verified MCM2 Biomarker For Bladder Cancer Diagnostics Phase III - Development of Digital Pathology Software to Aid Diagnosis of Bladder Cancer
